Cardiometabolic Health Congress

OCTOBER 10, 2024

These innovative companies leverage AI to develop cutting-edge diagnostic tools, predictive analytics, and personalized medicine approaches. This exciting overview highlights the top 10 AI-powered cardiometabolic startups poised to make significant impacts in 2025.

Innovation 52

Innovation Technology Kidney Disease Chronic Disease 52

DAIC

JULY 9, 2024

The American Heart Association, commemorating its 100th year, has announced its volunteer leadership for fiscal year 2024-2025, which includes Keith Churchwell, MD, FAHA, a cardiologist renowned as a health equity champion, and Marsha Jones, an executive leader in workplace diversity and inclusion. in Pittsburgh.

Innovation 111

Innovation Health Disparities Cardiovascular Disease Medicaid 111

DAIC

MARCH 18, 2024

milla1cf Mon, 03/18/2024 - 07:30 March 18, 2024 — SS Innovations International, Inc. , Dr. Srivastava said: “SS Innovations is dedicated to improving patient access and optimizing surgical outcomes with our accessible and cost-effective surgical robotic system. The mitral valve disease market size was valued at $2.5 from 2022 to 2031.

Innovation 105

Innovation Bicuspid/Mitral Exercise Technology 105

DAIC

JULY 29, 2024

mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. JenaValve presented positive results of its U.S.

Innovation 98

Innovation Aortic valve Aortic CMS 98

DAIC

JULY 15, 2024

Combined with Edwards’ existing mitral innovations, the acquisition enhances the company’s TMVR technologies to address large unmet structural heart patient needs and support sustainable long-term growth. Edwards’ SAPIEN M3 remains on track to become the first approved transfemoral TMVR system in Europe by the end of 2025.

Bicuspid/Mitral 105

Bicuspid/Mitral Tricuspid Technology Innovation 105

DAIC

MAY 31, 2024

Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally. in 2024 and approximately $0.17

Peripheral Arterial Disease 104

Peripheral Arterial Disease Innovation Coronary Artery Disease Cardiovascular Interventions 104

DAIC

APRIL 5, 2024

With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD).

Cardiovascular Interventions 105

Cardiovascular Interventions Technology Innovation Angina 105